Abstract
Preclinical studies suggest that bortezomib, through inhibition of nuclear factor-κB (NF-κB) activation, may enhance the effects of radioimmunotherapy. This phase I trial was designed to determine the maximum tolerated dose (MTD) of weekly bortezomib induction combined with Y-90-ibritumomab tiuxetan followed at the time of count recovery by weekly bortezomib consolidation in patients with relapsed/refractory follicular or transformed non-Hodgkin lymphoma. Grade 3 or 4 toxicities were observed in eight of nine treated patients, and all but one of these toxicities were hematologic. One patient had grade 3 cardiotoxicity. A dose limiting toxicity (DLT) of grade 4 thrombocytopenia was observed in two of three patients treated with bortezomib at 1.6 mg/m2, resulting in a MTD of 1.3 mg/m2. The overall response rate was 89% (two complete response [CR], six partial response [PR], one stable disease [SD]), with a median progression-free survival of 6.5 months (range: 3-22.5+ months). A phase II trial at the MTD is under way to better define the toxicity and effectiveness of this regimen.
Original language | English (US) |
---|---|
Pages (from-to) | 497-502 |
Number of pages | 6 |
Journal | Leukemia and Lymphoma |
Volume | 54 |
Issue number | 3 |
DOIs | |
State | Published - Mar 1 2013 |
Keywords
- Bortezomib
- Follicular lymphoma
- Y-90-ibritumomab tiuxetan
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research